Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A ...Middle East

SHANGHAI, Jan. 3, 2024 /PRNewswire/ -- Belief BioMed Group (BBM), an industry-leading biotech company focusing on innovative gene therapies, announced the completion of first subject dosing in its registrational clinical trial (CTR20233400) of BBM-H803, a gene therapy for hemophilia A,...

Hence then, the article about belief biomed successfully completed dosing of first subject in the registrational clinical trial for hemophilia a was published today ( Wednesday 03/01/2024 - 01:12 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Belief BioMed Successfully Completed Dosing of First Subject in the Registrational Clinical Trial for Hemophilia A )

Also on site :

• Trump administration efforts to shift blame for ICE shooting wreak havoc on Minnesota US attorney’s office
• Mizzou picks up transfer commitment from former B1G DB, 4-star recruit in 2025
• Lanes blocked in northwest suburban intersection after multi-vehicle crash